Seborrheic dermatitis (SD) is a common dermatological disorder that varies greatly in severity between individuals and with time. The etiology of this disease is poorly understood. Early investigators focused on the role of Malassezia (previously Pityrosporum) yeasts in the development of SD. Some researchers have hypothesized that there is an immunological component to SD and that this disease is caused by an altered immune response to Malassezia yeasts. However, other researchers view this condition as the result of hyperproliferation. Both antifungal and anti-inflammatory preparations have been used to treat SD effectively and safely. The wide range of antifungal formulations available (creams, shampoos, oral drugs) provides safe, effective and flexible treatment options for SD.

1.
Gupta AK, Nicol K, Batra R: Role of antifungal agents in the treatment of seborrheic dermatitis. Am J Clin Dermatol, in press.
2.
Farthing CF, Staughton RCD, Rowland Payne CME: Skin disease in homosexual patients with acquired immune deficiency syndrome (AIDS) and lesser forms of human T cell leukaemia virus (HTLV III) disease. Clin Exp Dermatol 1985;10:3–12.
3.
Smith KJ, Skelton HG, Yeager J, Ledsky R, McCarthy W, Baxter D, Turiansky GW, Wagner KF, Turianski G: Cutaneous findings in HIV-1-positive patients: A 42-month prospective study. Military Medical Consortium for the Advancement of Retroviral Research (MMCARR). J Am Acad Dermatol 1994;31:746–754.
4.
Faergemann J, Johansson S, Back O, Scheynius A: An immunologic and cultural study of Pityrosporum folliculitis. J Am Acad Dermatol 1986;14:429–433.
5.
Gupta AK: A random survey concerning aspects of acne rosacea (abstract). J Cutan Med Surg 2001;5:38.
6.
Sunenshine PJ, Schwartz RA, Janniger CK: Tinea versicolor: An update. Cutis 1998;61:65–68, 71–72.
7.
Zug KA, Palay DA, Rock B: Dermatologic diagnosis and treatment of itchy red eyelids. Surv Ophthalmol 1996;40:293–306.
8.
Kligman AM, McGinley KJ, Leyden JL: The nature of dandruff. J Soc Cosmet Chemists 1976;27:111–139.
9.
McGinley KJ, Leyden JJ, Marples RR, Kligman AM: Quantitative microbiology of the scalp in non-dandruff, dandruff, and seborrheic dermatitis. J Invest Dermatol 1975;64:401–405.
10.
Crespo Erchiga V, Ojeda Martos A, Vera Casano A, Crespo Erchiga A, Sanchez Fajardo F: Malassezia globosa as the causative agent of pityriasis versicolor. Br J Dermatol 2000;143:799–803.
11.
Nakabayashi A, Sei Y, Guillot J: Identification of Malassezia species isolated from patients with seborrhoeic dermatitis, atopic dermatitis, pityriasis versicolor and normal subjects. Med Mycol 2000;38:337–341.
12.
Gemmer CM, DeAngelis YM, Theelen B, Boekhout T, Dawson JT Jr: Fast, noninvasive method for molecular detection and differentiation of Malassezia yeast species on human skin and application of the method to dandruff microbiology. J Clin Microbiol 2002;40:3350–3357.
13.
Gupta AK, Kohli Y, Summerbell RC, Faergemann J: Quantitative culture of Malassezia species from different body sites of individuals with or without dermatoses. Med Mycol 2001;39:243–251.
14.
Kim SC, Kim HU: The distribution of Malassezia species on the normal human skin according to body region. Korean J Med Mycol 2000;5:120–128.
15.
Faergemann J: Management of seborrheic dermatitis and pityriasis versicolor. Am J Clin Dermatol 2000;1:75–80.
16.
Bergbrant IM, Faergemann J: Adherence of Malassezia furfur to human stratum corneum cells in vitro: A study of healthy individuals and patients with seborrhoeic dermatitis. Mycoses 1994;37:217–219.
17.
Faergemann J, Bergbrant IM, Dohse M, Scott A, Westgate G: Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: Characterization of inflammatory cells and mediators in the skin by immunohistochemistry. Br J Dermatol 2001;144:549–556.
18.
Neuber K, Kroger S, Gruseck E, Abeck D, Ring J: Effects of Pityrosporum ovale on proliferation, immunoglobulin (IgA, G, M) synthesis and cytokine (IL-2, IL-10, IFN-γ) production of peripheral blood mononuclear cells from patients with seborrhoeic dermatitis. Arch Dermatol Res 1996;288:532–536.
19.
Hay RJ, Graham-Brown RA: Dandruff and seborrhoeic dermatitis: Causes and management. Clin Exp Dermatol 1997;22:3–6.
20.
Baroni A, Perfetto B, Paoletti I, Ruocco E, Canozo N, Orlando M, Buommino E: Malassezia furfur invasiveness in a keratinocyte cell line (HaCat): Effects on cytoskeleton and on adhesion molecule and cytokine expression. Arch Dermatol Res 2001;293:414–419.
21.
Watanabe S, Kano R, Sato H, Nakamura Y, Hasegawa A: The effects of Malassezia yeasts on cytokine production by human keratinocytes. J Invest Dermatol 2001;116:769–773.
22.
Midgley G, Hay RJ: Serological responses to Pityrosporum (Malassezia) in seborrhoeic dermatitis demonstrated by ELISA and Western blotting. Bull Soc Fr Mycol Méd 1988;17:267–276.
23.
Bergbrant IM, Faergemann J: Seborrhoeic dermatitis and Pityrosporum ovale: A cultural and immunological study. Acta Derm Venereol 1989;69:332–335.
24.
Midgley G: The lipophilic yeasts: State of the art and prospects. Med Mycol 2000;38(suppl 1):9–16.
25.
Bergbrant IM, Andersson B, Faergemann J: Cell-mediated immunity to Malassezia furfur in patients with seborrhoeic dermatitis and pityriasis versicolor. Clin Exp Dermatol 1999;24:402–406.
26.
Parry ME, Sharpe GR: Seborrhoeic dermatitis is not caused by an altered immune response to Malassezia yeast. Br J Dermatol 1998;139:254–263.
27.
McGrath J, Murphy GM: The control of seborrhoeic dermatitis and dandruff by antipityrosporal drugs. Drugs 1991;41:178–184.
28.
Riciputo RM, Oliveri S, Micali G, Sapuppo A: Phospholipase activity in Malassezia furfur pathogenic strains. Mycoses 1996;39:233–235.
29.
Faergemann J, Fredriksson T: Tinea versicolor with regard to seborrheic dermatitis: An epidemiological investigation. Arch Dermatol 1979;115:966–968.
30.
Binder RL, Jonelis FJ: Seborrheic dermatitis in neuroleptic-induced parkinsonism. Arch Dermatol 1983;119:473–475.
31.
Ford GP, Farr PM, Ive FA, Shuster S: The response of seborrhoeic dermatitis to ketoconazole. Br J Dermatol 1984;111:603–607.
32.
Ortonne JP, Lacour JP, Vitetta A, Le Fichoux Y: Comparative study of ketoconazole 2% foaming gel and betamethasone dipropionate 0.05% lotion in the treatment of seborrhoeic dermatitis in adults. Dermatology 1992;184:275–280.
33.
Gueho E, Faergemann J, Lyman C, Anaissie EJ: Malassezia and Trichosporon: Two emerging pathogenic basidiomycetous yeast-like fungi. J Med Vet Mycol 1994;32(suppl 1):367–378.
34.
Shuster S: The aetiology of dandruff and the mode of action of therapeutic agents. Br J Dermatol 1984;111:235–242.
35.
Orentreich N, Taylor EH, Berger RA, Auerbach R: Comparative study of two antidandruff preparations. J Pharm Sci 1969;58:1279–1280.
36.
Faergemann J: Propylene glycol in the treatment of seborrheic dermatitis of the scalp: A double-blind study. Cutis 1988;42:69–71.
37.
Rapaport M: A randomized, controlled clinical trial of four anti-dandruff shampoos. J Int Med Res 1981;9:152–156.
38.
Marks R, Pearse AD, Walker AP: The effects of a shampoo containing zinc pyrithione on the control of dandruff. Br J Dermatol 1985;112:415–422.
39.
Unholzer A, Varigos G, Nicholls D, Schinzel S, Nietsch KH, Ulbricht H, Korting HC: Ciclopiroxolamine cream for treating seborrheic dermatitis: A double-blind parallel group comparison. Infection 2002;30:373–376.
40.
Piérard-Franchimont C, Piérard GE: A double-blind placebo-controlled study of ketoconazole + desonide gel combination in the treatment of facial seborrheic dermatitis. Dermatology 2002;204:344–347.
41.
Squire RA, Goode K: A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis. J Dermatol Treat 2002;13:51–60.
42.
Shemer A, Nathansohn N, Kaplan B, Weiss G, Newman N, Trau H: Treatment of scalp seborrheic dermatitis and psoriasis with an ointment of 40% urea and 1% bifonazole. Int J Dermatol 2000;39:532–534.
43.
Shiri J, Amichai B: Treatment of seborrheic dermatitis of the scalp and dandruff with a shampoo containing 1% bifonazole (Agispor shampoo). J Dermatol Treat 1998;9:95–96.
44.
Wigger-Alberti W, Kluge K, Elsner P: Clinical effectiveness and tolerance of climbazole-containing dandruff shampoo in patients with seborrheic scalp eczema (in German). Schweiz Rundsch Med Prax 2001;90:1346–1349.
45.
Parsad D, Pandhi R, Negi KS, Kumar B: Topical metronidazole in seborrheic dermatitis – A double-blind study. Dermatology 2001;202:35–37.
46.
Faergemann J: Seborrhoeic dermatitis and Pityrosporum orbiculare: Treatment of seborrhoeic dermatitis of the scalp with miconazole-hydrocortisone (Daktacort), miconazole and hydrocortisone. Br J Dermatol 1986;114:695–700.
47.
Rigopoulos D, Katsambas A, Antoniou C, Theocharis S, Stratigos J: Facial seborrheic dermatitis treated with fluconazole 2% shampoo. Int J Dermatol 1994;33:136–137.
48.
Caputo R, Barbareschi M: Itraconazole: New horizons. G Ital Dermatol Venereol 2002;137:1–7.
49.
Faergemann J, Jones JC, Hettler O, Loria Y: Pityrosporum ovale (Malassezia furfur) as the causative agent of seborrhoeic dermatitis: New treatment options. Br J Dermatol 1996;134(suppl 46):12–15.
50.
Gupta AK, Yokou M, Arika T, Bucks D: Evaluation of the in vitro and in vivo efficacy of butenafine hydrochloride cream 1% against Malassezia furfur species and seborrheic dermatitis. J Dermatol Treat 2000;11:79–83.
51.
Braza TJ, Di Carlo JB, Soon SL, McCall CO: Tacrolimus 0.1% ointment for seborrhoeic dermatitis: An open-label pilot study. Br J Dermatol 2003;148:1242–1244.
52.
Crutchfield CE III: Pimecrolimus: A new treatment for seborrheic dermatitis. Cutis 2002;70:207–208.
53.
Dreno B, Moyse D: Lithium gluconate in the treatment of seborrhoeic dermatitis: A multicenter, randomised, double-blind study versus placebo. Eur J Dermatol 2002;12:549–552.
54.
Dreno B, Chosidow O, Revuz J, Moyse D: Lithium gluconate 8% vs ketoconazole 2% in the treatment of seborrhoeic dermatitis: A multicentre, randomized study. Br J Dermatol 2003;148:1230–1236.
55.
Ghannoum MA, Kuhn DM: Voriconazole – Better chances for patients with invasive mycoses. Eur J Med Res 2002;7:242–256.
56.
Gupta AK, Einarson TR, Summerbell RC, Shear NH: An overview of topical antifungal therapy in dermatomycoses: A North American perspective. Drugs 1998;55:645–674.
57.
Elewski BE: Mechanisms of action of systemic antifungal agents. J Am Acad Dermatol 1993;28:S28–S34.
58.
Rosen T, Schell BJ, Orengo I: Anti-inflammatory activity of antifungal preparations. Int J Dermatol 1997;36:788–792.
59.
Faergemann J: Treatment of seborrhoeic dermatitis with oral terbinafine? Lancet 2001;358:170.
60.
Scaparro E, Quadri G, Virno G, Orifici C, Milani M: Evaluation of the efficacy and tolerability of oral terbinafine (Daskil) in patients with seborrhoeic dermatitis: A multicentre, randomized, investigator-blinded, placebo-controlled trial. Br J Dermatol 2001;144:854–857.
61.
Chosidow O, Maurette C, Dupuy P: Randomized, open-labeled, non-inferiority study between ciclopiroxolamine 1% cream and ketoconazole 2% foaming gel in mild to moderate facial seborrheic dermatitis. Dermatology 2003;206:233–240.
62.
Abrams BB, Hänel H, Hoehler T: Ciclopirox olamine: A hydroxypyridone antifungal agent. Clin Dermatol 1992;9:471–477.
63.
Hanel H, Smith-Kurtz E, Pastowsky S: Therapy of seborrheic eczema with an antifungal agent with an antiphlogistic effect. Mycoses 1991;34(suppl 1):91–93.
64.
Korting HC, Grundmann-Kollmann M: The hydroxypyridones: A class of antimycotics of its own. Mycoses 1997;40:243–247.
65.
Nakagawa H, Etoh T, Yokota Y, Ikeda F, Hatano K, Teratani N, Shimomura K, Mine Y, Amaya T: Tacrolimus has antifungal activities against Malassezia furfur isolated from healthy adults and patients with atopic dermatitis. Clin Drug Invest 1996;12:245–250.
66.
Pirkhammer D, Seeber A, Honigsmann H, Tanew A: Narrow-band ultraviolet B (TL-01) phototherapy is an effective and safe treatment option for patients with severe seborrhoeic dermatitis. Br J Dermatol 2000;143:964–968.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.